CRIS Current Research Information System

BON, ISABELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.451
EU - Europa 2.178
AS - Asia 1.173
AF - Africa 211
SA - Sud America 16
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.039
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.445
GB - Regno Unito 547
CN - Cina 476
SE - Svezia 436
IT - Italia 383
SG - Singapore 321
DE - Germania 267
VN - Vietnam 166
IN - India 125
IE - Irlanda 119
TG - Togo 109
UA - Ucraina 94
RU - Federazione Russa 85
FR - Francia 79
EE - Estonia 45
ZA - Sudafrica 44
JO - Giordania 36
BG - Bulgaria 33
NG - Nigeria 33
BE - Belgio 23
CH - Svizzera 19
CI - Costa d'Avorio 18
FI - Finlandia 15
ID - Indonesia 11
BR - Brasile 9
HK - Hong Kong 7
IR - Iran 7
NL - Olanda 7
TR - Turchia 7
ES - Italia 6
SC - Seychelles 6
AU - Australia 5
PT - Portogallo 5
JP - Giappone 4
LB - Libano 4
RO - Romania 4
UZ - Uzbekistan 4
CL - Cile 3
EU - Europa 3
MX - Messico 3
CA - Canada 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GR - Grecia 2
NZ - Nuova Zelanda 2
PE - Perù 2
AL - Albania 1
AR - Argentina 1
AZ - Azerbaigian 1
BD - Bangladesh 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MD - Moldavia 1
MS - Montserrat 1
MY - Malesia 1
SI - Slovenia 1
VE - Venezuela 1
Totale 7.039
Salva come PNG Salva come JPEG
Città #
Southend 484
Fairfield 395
Chandler 337
Singapore 289
Ashburn 258
Santa Clara 218
Woodbridge 209
Seattle 184
Wilmington 170
Ann Arbor 164
Houston 164
Dong Ket 148
Princeton 138
Cambridge 133
Dublin 119
Lomé 109
Boardman 93
Bologna 89
Florence 72
Nanjing 59
Westminster 54
Jacksonville 52
Padova 49
Berlin 45
Turin 39
Amman 36
Abeokuta 33
Sofia 33
Beijing 32
Jinan 30
Shenyang 29
San Diego 27
Redmond 26
Saint Petersburg 24
Brussels 23
Hebei 22
Abidjan 18
New York 18
Dearborn 16
Los Angeles 16
Tianjin 16
Bremen 15
Milan 15
Nanchang 15
Zhengzhou 15
Des Moines 14
Helsinki 14
Ningbo 14
Jiaxing 13
Olalla 13
Bern 12
Falls Church 12
Rome 12
Guangzhou 10
Hangzhou 10
London 10
Mülheim 10
Phoenix 10
Taizhou 10
Bühl 9
Changsha 9
Haikou 9
Jakarta 9
Shanghai 9
Wuhan 8
Atlanta 7
Lanzhou 7
Paris 7
Taiyuan 7
Chicago 6
Fuzhou 6
Mahé 6
Istanbul 5
Monmouth Junction 5
Norwalk 5
Trabia 5
Ardabil 4
Divinópolis 4
Hong Kong 4
Kunming 4
Redwood City 4
Shenzhen 4
Shijiazhuang 4
São Paulo 4
Verona 4
Xi'an 4
Amsterdam 3
Castenaso 3
Chengdu 3
Falkenstein 3
Hefei 3
Hyderabad 3
Kuban 3
Medolla 3
Moscow 3
Muizenberg 3
Pescara 3
Plauen 3
Qingdao 3
Quanzhou 3
Totale 4.895
Salva come PNG Salva come JPEG
Nome #
Acute onset myopericarditis as unusual presentation of primary HIV infection 198
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells 179
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 171
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection 166
Discordant resistance interpretations in multi-treated HIV-1 patients 160
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 152
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 152
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. 142
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 140
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 136
Antiretroviral molecules and cardiovascular diseases. 132
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures 132
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. 131
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 131
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke 130
Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. 127
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 126
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 126
Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. 126
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 124
Effects of Antiretroviral Molecules on Survival and Gene Expression of an Osteoblast-like Cell Line 123
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns 123
Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results 120
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 119
HIV-related mechanisms in atherosclerosis and cardiovascular diseases. 119
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 117
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy 116
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case report. 116
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 114
null 113
HIV and kidney: A dangerous liaison 113
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 113
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 111
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 110
V3 net charge: additional tool in HIV-1 tropism prediction 108
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 107
Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. 106
An HIV type 2 case series in Italy: A phylogenetic analysis 106
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. 105
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 102
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: Results from the DIVA study group 99
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 99
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 98
Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? 97
Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy 96
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 93
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study) 88
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. 88
Improving counterfactual reasoning with kernelised dynamic mixing models 87
Significant association between statin-associated myalgia and Vitamin D deficiency among treated HIV-infected patients 86
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 84
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 83
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy 82
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 81
HIV-1 gp120 impairs the differentiation and survival of cord blood CD34+ HPCs induced to the erythroid lineage. 77
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 74
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy 73
Restriction Factors expression decreases in HIV-1 patients after cART 73
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. 72
Hepatitis A virus in a medical setting in Madagascar: a lesson for public health 71
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 67
HBsAg seroreversion in HBsAg-negative/HBcAb-positive patients with HIV infection treated with direct-acting antivirals for HCV: A retrospective study 66
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 56
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 44
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir 31
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. 28
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir. 27
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 26
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. 22
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir 21
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 15
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 9
Totale 7.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.026 0 0 0 0 0 154 184 203 229 115 64 77
2020/2021852 188 62 27 28 28 56 7 36 111 44 37 228
2021/20221.375 71 75 66 147 103 62 31 107 57 230 252 174
2022/20231.577 142 231 59 193 138 96 38 100 271 57 171 81
2023/2024404 25 66 39 52 31 81 19 24 9 29 21 8
2024/2025951 72 247 133 129 295 75 0 0 0 0 0 0
Totale 7.255